SCHEMBL2300930

SCHEMBL2300930

C=C(NC(=O)c1cc(-c2ccc(NC(=O)Nc3ccccc3F)cc2)no1)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
RAB9A P51151 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
KDM4E B2RXH2 2/20 0.56
RXFP1 Q9HBX9 1/20 0.56
ALDH1A1 P00352 1/20 0.54
CSGALNACT1 Q8TDX6 13/20 0.54
NPC1 O15118 2/20 0.47
HTT P42858 2/20 0.47
MAPT P10636 1/20 0.47
KDR P35968 2/20 0.47
EPHB4 P54760 1/20 0.47
TEK Q02763 1/20 0.47
POLB P06746 1/20 0.46
KIT P10721 1/20 0.46
FLT3 P36888 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3232661 0.95 SMN1; SMN2 (0.58) MEN1KMT2ARAB9ASMN1; SMN2KDM4E
SCHEMBL2293726 0.90 SMN1; SMN2 (0.62) MEN1KMT2ARAB9ASMN1; SMN2KDM4E
SCHEMBL2297791 0.85 RAB9A (0.58) MEN1KMT2ARAB9ASMN1; SMN2KDM4E
SCHEMBL2296319 0.83 CSGALNACT1 (0.64) MEN1KMT2ASMN1; SMN2KDM4EALDH1A1
SCHEMBL2298959 0.80 MEN1 (0.53) MEN1KMT2ARAB9ASMN1; SMN2KDM4E
SCHEMBL2296895 0.80 CSGALNACT1 (0.60) MEN1KMT2ARAB9ASMN1; SMN2KDM4E
SCHEMBL2296876 0.80 CSGALNACT1 (0.60) MEN1KMT2ARAB9ASMN1; SMN2KDM4E
SCHEMBL2298940 0.80 CSGALNACT1 (0.82) CSGALNACT1
SCHEMBL2297151 0.80 CSGALNACT1 (0.82) CSGALNACT1
SCHEMBL2294524 0.79 CSGALNACT1 (0.59) MEN1KMT2ARAB9ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835428-B2 Diacylglycerol acyltransferase inhibitors Piramal Enterprises Limited (IN) 2014-09-16 US claimed
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US claimed
WO-2010023609-A1 OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-03-04 WO claimed
US-8835428-B2 Diacylglycerol acyltransferase inhibitors Piramal Enterprises Limited (IN) 2014-09-16 US disclosed
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US disclosed
WO-2010023609-A1 OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS DGAT1, DGAT2, DLAT MEN1 4530/4885KMT2A 1450/4885RAB9A 3753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.